ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Bliss GVS Pharma was fined Rs. 1,80,000 (excluding GST) by BSE and NSE for failing to appoint a woman director. The fine has been paid to the regulators.
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
Bliss GVS Pharma Ltd reported revenue from operations of ₹313.4 Cr (+28.2% YoY) and net profit of ₹53.3 Cr (+86.4% YoY) for Q2 FY27.
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bliss GVS Pharma Ltd scheduled a board meeting for October 29, 2026, to approve the company's unaudited financial results for the quarter ending September 30, 2026.
Bliss GVS Pharma Ltd has filed its quarterly shareholding pattern report for the period ended September 30, 2026.
Bliss GVS Pharma has issued a postal ballot notice to seek member approval for the appointment of three directors. This follows a recent change in control.
Bliss GVS Pharma Limited allotted 53,500 equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's total paid-up share capital.
Bliss GVS Pharma announced the reclassification of its erstwhile promoter group to the public category following a change in control via an open offer.